Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective.
Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A. Badar T, et al. Bone Marrow Transplant. 2018 Sep;53(9):1210-1213. doi: 10.1038/s41409-018-0178-5. Epub 2018 Apr 20. Bone Marrow Transplant. 2018. PMID: 29679076 No abstract available.
Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms.
Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Katamesh B, et al. Among authors: badar t. Ann Hematol. 2023 Jan;102(1):211-212. doi: 10.1007/s00277-022-05016-1. Epub 2022 Nov 4. Ann Hematol. 2023. PMID: 36331566 No abstract available.
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
Abdelmagid MG, Al-Kali A, Litzow MR, Begna KH, Hogan WJ, Patnaik MS, Hashmi SK, Elliott MA, Alkhateeb H, Karrar OS, Fleti F, Elnayir MH, Rivera CE, Murthy HS, Foran JM, Kharfan-Dabaja MA, Badar T, Viswanatha DS, Reichard KK, Gangat N, Tefferi A. Abdelmagid MG, et al. Among authors: badar t. Blood Cancer J. 2023 Aug 11;13(1):122. doi: 10.1038/s41408-023-00891-x. Blood Cancer J. 2023. PMID: 37567878 Free PMC article.
Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience.
Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Bessonen K, Gangat N, Begna K, Mangaonkar A, Patnaik M, Hogan WJ, Tefferi A, Litzow M, Shah MV, Yi CA, Foran J, Badar T, Alkhateeb HB, Al-Kali A. Katamesh B, et al. Among authors: badar t. Blood Adv. 2023 Apr 25;7(8):1351-1355. doi: 10.1182/bloodadvances.2022007937. Blood Adv. 2023. PMID: 36477202 Free PMC article. No abstract available.
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
Gurney M, Chekkaf I, Baranwal A, Basmaci R, Katamesh B, Greipp P, Foran JM, Badar T, Mangaonkar AA, Begna KH, Gangat N, Patnaik MM, Litzow MR, Shah MV, Viswanatha DS, He R, Alkhateeb HB, Al-Kali A. Gurney M, et al. Among authors: badar t. Br J Haematol. 2023 Jul;202(2):279-283. doi: 10.1111/bjh.18850. Epub 2023 May 5. Br J Haematol. 2023. PMID: 37144345
91 results